Latest Content

Attitudes With Latitude About My Cancer

April 24th 2024, 3:00pm

By Phillip Belfiori

Article

Even though I lost my hair from cancer treatment, I didn't let that stop me from styling my hair with attitude.

Enhertu Marks First Therapy Approved Across HER2-Positive Solid Tumors

April 24th 2024, 1:00pm

By Ashley Chan

Article

Treatment with Enhertu “is an unprecedented approval” for patients with HER2-positive solid tumors who did not have many options, an expert told CURE®.

Tecentriq, Cabometyx May Not Improve Survival Over Chemo in NSCLC

April 23rd 2024, 9:00pm

By Alex Biese

Article

Tecentriq plus Cabometyx conferred no overall survival benefit when compared with chemotherapy, a study showed.

FDA Approves Ojemda for Pediatric Low-Grade Glioma

April 23rd 2024, 7:01pm

By Alex Biese

Article

The FDA has granted accelerated approval to Ojemda for patients 6 months and older with relapsed or refractory pediatric low-grade glioma with a BRAF fusion or rearrangement, or BRAF V600 mutation.

Woodpecker Wisdom Unfolds a Cancer Analogy

April 23rd 2024, 5:00pm

By Georgia Hurst

Article

While strolling through the woods, my eyes landed on a woodpecker, whose actions sparked a cancer analogy in my mind.

FDA Approves Lutathera for Pediatric GEP-NETs

April 23rd 2024, 4:38pm

By Brielle Benyon

Article

Lutathera was approved for patients 12 or older with SSTR-positive gastroenteropancreatic neuroendocrine tumors, the FDA announced.

Ziftomenib Granted Breakthrough Therapy Designation by FDA in R/R AML

April 23rd 2024, 3:00pm

By Alex Biese

Article

The investigational drug ziftomenib is currently being evaluated for patients with relapsed/refractory NPM1-mutant acute myeloid leukemia.

Speaking Openly About Cancer-Related Fears

April 23rd 2024, 1:00pm

By Joe Guastella

Article

When my wife was diagnosed with stage 3B melanoma, we decided to openly speak about our fears.

FDA Approves Anktiva Plus BCG for Certain Bladder Cancer Subset

April 22nd 2024, 11:48pm

By Alex Biese

Article

A treatment combination of Anktiva and Bacillus Calmette-Guérin was approved by the FDA for certain patients with non-muscle-invasive bladder cancer.

Insomnia Therapy May Reduce Cognitive Impairment in Cancer Survivors

April 22nd 2024, 9:00pm

By Ashley Chan

Article

A cognitive behavioral therapy for insomnia may help cancer survivors, along with ways to manage insomnia via sleep pressure, an expert told CURE®.

What Patients Can Do as Racial Disparities Persist in Prostate Cancer

April 22nd 2024, 7:00pm

By Alex Biese

Article

Patient/provider trust, education and lifestyle choices are crucial as Black men face higher incidence and mortality in prostate cancer, experts said.